These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37373710)

  • 1. Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on "Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS).
    Hughes DA; Deegan P; Giraldo P; Göker-Alpan Ö; Lau H; Lukina E; Revel-Vilk S; Scarpa M; Botha J; Gadir N; Zimran A;
    J Clin Med; 2023 Jun; 12(12):. PubMed ID: 37373710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS).
    Mistry PK; Kishnani PS; Balwani M; Charrow JM; Hull J; Weinreb NJ; Cox TM
    J Clin Med; 2023 May; 12(9):. PubMed ID: 37176709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS).
    Hughes DA; Deegan P; Giraldo P; Göker-Alpan Ö; Lau H; Lukina E; Revel-Vilk S; Scarpa M; Botha J; Gadir N; Zimran A;
    J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36079085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reply to van der Pluijm et al. Comment on "Weitzman et al. Resistance to Antimalarial Monotherapy Is Cyclic.
    Calfon-Peretz O; Weitzman R; Amitay M; Samson AO
    J Clin Med; 2022 May; 11(11):. PubMed ID: 35683361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzyme replacement and substrate reduction therapy for Gaucher disease.
    Shemesh E; Deroma L; Bembi B; Deegan P; Hollak C; Weinreb NJ; Cox TM
    Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD010324. PubMed ID: 25812601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of 26 patients with type 3 Gaucher disease: A descriptive analysis from the Gaucher Outcome Survey.
    Schwartz IVD; Göker-Alpan Ö; Kishnani PS; Zimran A; Renault L; Panahloo Z; Deegan P;
    Mol Genet Metab Rep; 2018 Mar; 14():73-79. PubMed ID: 29326879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined miglustat and enzyme replacement therapy in two patients with type 1 Gaucher disease: two case reports.
    Amato D; Patterson MA
    J Med Case Rep; 2018 Jan; 12(1):19. PubMed ID: 29373994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report.
    Giuffrida G; Lombardo R; Di Francesco E; Parrinello L; Di Raimondo F; Fiumara A
    J Med Case Rep; 2016 Nov; 10(1):315. PubMed ID: 27821156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reply to Böning et al. Comment on "Ceruti et al. Temporal Changes in the Oxyhemoglobin Dissociation Curve of Critically Ill COVID-19 Patients.
    Ceruti S; Minotti B; Glotta A; Biggiogero M; Bona G; Marzano M; Greco P; Spagnoletti M; Garzoni C; Bendjelid K
    J Clin Med; 2022 Aug; 11(15):. PubMed ID: 35956162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reply to Weiss, H.-R. Comment on "Costa et al. The Effectiveness of Different Concepts of Bracing in Adolescent Idiopathic Scoliosis (AIS): A Systematic Review and Meta-Analysis.
    Costa L; Schlösser TPC; Kruyt MC; Castelein RM
    J Clin Med; 2022 Feb; 11(4):. PubMed ID: 35207191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme Replacement or Substrate Reduction? A Review of Gaucher Disease Treatment Options.
    Van Rossum A; Holsopple M
    Hosp Pharm; 2016 Jul; 51(7):553-63. PubMed ID: 27559188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Prospective Study to Evaluate the Possible Role of Cholecalciferol Supplementation on Autoimmunity in Hashimoto's Thyroiditis.
    Bhakat B; Pal J; Das S; Charaborty SK; SircarMedical NR; Kolkata ; RGKar ; NorthBengal ; Siliguri
    J Assoc Physicians India; 2023 Jan; 71(1):1. PubMed ID: 37116030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reply to Chen et al. Improvements in Outcomes and Expanding Indications for the Commando Procedure. Comment on "Giambuzzi et al. Surgical Aortic Mitral Curtain Replacement: Systematic Review and Metanalysis of Early and Long-Term Results.
    Giambuzzi I; Bonalumi G; Di Mauro M; Alamanni F; Zanobini M
    J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35329926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment patterns from 647 patients with Gaucher disease: An analysis from the Gaucher Outcome Survey.
    Deegan P; Fernandez-Sasso D; Giraldo P; Lau H; Panahloo Z; Zimran A
    Blood Cells Mol Dis; 2018 Feb; 68():218-225. PubMed ID: 27829541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sclerobanding Is a Novel Technique for the Treatment of Second- and Third-Degree Hemorrhoidal Disease. Reply to Jongen et al. Comment on "Pata et al. Sclerobanding (Combined Rubber Band Ligation with 3% Polidocanol Foam Sclerotherapy) for the Treatment of Second- and Third-Degree Hemorrhoidal Disease: Feasibility and Short-Term Outcomes.
    Pata F; Bracchitta LM; D'Ambrosio G; Bracchitta S
    J Clin Med; 2022 May; 11(11):. PubMed ID: 35683464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reply to Supady et al. On the Use of Hemadsorption with CytoSorb in Patients with Septic Shock. Comment on "Kogelmann et al. First Evaluation of a New Dynamic Scoring System Intended to Support Prescription of Adjuvant CytoSorb Hemoadsorption Therapy in Patients with Septic Shock.
    Kogelmann K; Hübner T; Schwameis F; Drüner M; Scheller M; Jarczak D
    J Clin Med; 2022 Feb; 11(5):. PubMed ID: 35268285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reply to Sanfilippo et al. Caution Is Warranted When Assessing Diastolic Function Using Transesophageal Echocardiography. Comment on "Kyle et al. Consensus Defined Diastolic Dysfunction and Cardiac Postoperative Morbidity Score: A Prospective Observational Study.
    Zawadka M; Kyle B; Shanahan H; Cooper J; Rogers A; Hamarneh A; Sivaraman V; Anwar S; Smith A
    J Clin Med; 2022 Jun; 11(12):. PubMed ID: 35743371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reply to Cione et al. Comment on "Moshirfar et al. Accuracy of Six Intraocular Lens Power Calculations in Eyes with Axial Lengths Greater than 28.0 mm.
    Moshirfar M; Durnford KM; Jensen JL; Beesley DP; Peterson TS; Darquea IM; Ronquillo YC; Hoopes PC
    J Clin Med; 2023 May; 12(9):. PubMed ID: 37176708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching from imiglucerase to miglustat for the treatment of French patients with Gaucher disease type 1: a case series.
    Serratrice C; Swiader L; Serratrice J
    J Med Case Rep; 2015 Jun; 9():146. PubMed ID: 26100396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reply to Ducreux, B.; Fauque, P. Comment on "Cannarella et al. DNA Methylation in Offspring Conceived after Assisted Reproductive Techniques: A Systematic Review and Meta-Analysis.
    Cannarella R; Crafa A; Calogero AE
    J Clin Med; 2022 Dec; 12(1):. PubMed ID: 36615055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.